Treatment she can plan on.

In RAPID-PsA, 58% of CIMZIA 200 mg Q2W-treated patients (n=138) vs. 24% of placebo-treated patients (n=136) achieved ACR20 at week 12.1*

For PsA patients

CIMZIA® (certolizumab pegol) is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).

NEXT: CIMZIA Design *The same patients may not have responded at each time point.